Universität zu Köln

Moinzadeh, Pia, Fonseca, Carmen, Hellmich, Martin, Shah, Ami A., Chighizola, Cecilia ORCID: 0000-0002-3787-9632, Denton, Christopher P. and Ong, Voon H. (2014). Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res. Ther., 16 (1). LONDON: BIOMED CENTRAL LTD. ISSN 1478-6362

Full text not available from this repository.

Abstract

Introduction: We assessed the profile and frequency of malignancy subtypes in a large single-centre UK cohort for patients with scleroderma (systemic sclerosis; SSc). We evaluated the cancer risk among SSc patients with different antibody reactivities and explored the temporal association of cancer with the duration between SSc onset and cancer diagnosis. Methods: We conducted a retrospective study of a well-characterised cohort of SSc patients attending a large tertiary referral centre, with clinical data collected from our clinical database and by review of patient records. We evaluated development of all cancers in this cohort, and comparison was assessed with the SSc cohort without cancer. The effect of demographics and clinical details, including antibody reactivities, were explored to find associations relevant to the risk for development of cancer in SSc patients. Results: Among 2,177 patients with SSc, 7.1% had a history of cancer, 26% were positive for anticentromere antibodies (ACAs), 18.2% were positive for anti-Scl-70 antibodies and 26.6% were positive for anti-RNA polymerase III (anti-RNAP) antibody. The major malignancy cancer subtypes were breast (42.2%), haematological (12.3%), gastrointestinal (11.0%) and gynaecological (11.0%). The frequency of cancers among patients with RNAP (14.2%) was significantly increased compared with those with anti-Scl-70 antibodies (6.3%) and ACAs (6.8%) (P < 0.0001 and P < 0.001, respectively). Among the patients, who were diagnosed with cancer within 36 months of the clinical onset of SSc, there were more patients with RNAP (55.3%) than those with other autoantibody specificities (ACA = 23.5%, P < 0.008; and anti-Scl-70 antibodies = 13.6%, P < 0.002, respectively). Breast cancers were temporally associated with onset of SSc among patients with anti-RNAP, and SSc patients with anti-RNAP had a twofold increased hazard ratio for cancers compared to patients with ACAs (P < 0.0001). Conclusions: Our study independently confirms, in what is to the best of our knowledge the largest population examined to date, that there is an association with cancer among SSc patients with anti-RNAP antibodies in close temporal relationship to onset of SSc, which supports the paraneoplastic phenomenon in this subset of SSc cases. An index of cautious suspicion should be maintained in these cases, and investigations for underlying malignancy should be considered when clinically appropriate.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Moinzadeh, Pia UNSPECIFIED UNSPECIFIED UNSPECIFIED Fonseca, Carmen UNSPECIFIED UNSPECIFIED UNSPECIFIED Hellmich, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Shah, Ami A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chighizola, Cecilia UNSPECIFIED orcid.org/0000-0002-3787-9632 UNSPECIFIED Denton, Christopher P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ong, Voon H. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-450435
DOI:	10.1186/ar4486
Journal or Publication Title:	Arthritis Res. Ther.
Volume:	16
Number:	1
Date:	2014
Publisher:	BIOMED CENTRAL LTD
Place of Publication:	LONDON
ISSN:	1478-6362
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OF-THE-LITERATURE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; POPULATION-BASED COHORT; BREAST-CANCER; LUNG-CANCER; SCLEROSIS; CELLS; TRANSCRIPTION; MALIGNANCY; RISK Multiple languages Rheumatology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/45043